A new nomenclature for fatty liver disease has been published : NAFLD is becoming MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and NASH is becoming MASH (Metabolic Dysfunction Associated Steatohepatitis).

2 million deaths per year worldwide are caused by Chronic Liver Disease (CLD). Globally, the most common cause of CLD is Non-Alcoholic Fatty Liver Disease (NAFLD) which is estimated to affect approximately 25% of the world population. 73% of patients with type 2 diabetes mellitus have NAFLD. Non-Alcoholic Steatohepatitis (NASH), a progressive form of NAFLD which combines fatty liver, liver inflammation and liver damage, is the 2nd most common aetiology of hepatocellular (HCC) requiring liver transplantation.

Join the 2023 NASH Club, a series of 3 full educational CME accredited interactive and hybrid event dedicated to all matters NAFLD-NASH. You will learn from 12 top experts from a wide range of medical specialties: Hepatologists, Diabetologists, Endocrinologists, General practitioners and Gastroenterologists coming from different EU countries.

Overall Learning Objectives

• Learn more about the importance of liver diseases early screening, including in primary point of care and the latest available tools and techniques to perform liver exams.
• Closing the loop: Understand how coordination between medical specialties can help optimize patient journey and care.
• Get to know current NAFLD-NASH treatment and future NASH treatment options including drugs in phase 3.